Immunoblotting analysis showed that the expression of Nrf2 and HO-1 proteins was reduced in the CKD group, along with increased levels of Keap1, compared to those in the Sham group, which was attenuated by losartan treatment (Figure 6D). This evidence concerns the gene NFE2L2 and chronic kidney disease.